Pag-aaral pangklinika para sa Melanoma sa Iowa
12 pag-aaral para sa Melanoma ang naghahanap ng mga kalahok sa mga site sa Iowa.
Mga Lungsod sa Iowa
- Cedar Rapids10 pag-aaral
- Des Moines5 pag-aaral
- Ames3 pag-aaral
- Fort Dodge3 pag-aaral
- Marshalltown3 pag-aaral
Opisyal na teksto ng pag-aaral (English)
BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- at 10 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05136196A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
- McFarland Clinic - Boone, Boone
- at 10 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 15, 2026 · NCT04511013Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- at 13 pa
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Set 2, 2026 · NCT05334069Project: Every Child for Younger Patients With Cancer
- Blank Children's Hospital, Des Moines
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
Nagre-recruitObservasyonal na pag-aaral
Hanggang edad 25 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT02402244A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
- University of Iowa, Iowa City
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT04895709Integrated Cancer Repository for Cancer Research
- Methodist Jennie Edmundson Hospital, Council Bluffs
- Covenant Medical Center, Inc, Waterloo
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 19 hanggang 110 · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT02012699MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
- University of Iowa, Iowa City
Nagre-recruitPhase 1/2
Edad 18 hanggang 90 · Lahat ng kasarian · Na-update Hun 10, 2026 · NCT05655312A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- University of Iowa, Iowa City
Nagre-recruitPhase 2/3
Lahat ng edad · Lahat ng kasarian · Na-update Abr 2, 2026 · NCT06581406Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- University of Iowa Healthcare Cancer Services Quad Cities, Bettendorf
- Physicians' Clinic of Iowa PC, Cedar Rapids
- at 10 pa
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06418204Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma
- University of Iowa, Iowa City
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT04903119Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
- University of Iowa, Iowa City
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 3, 2025 · NCT06194929SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Iowa City
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.